The nation of Zimbabwe has rejected a major American health deal valued at 367 million US dollars (272 million pounds) over five years over the United States' request for confidential biological samples.
This rejection became public after a official document from December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
An official representative has since stated that the US was demanding access to genetic material for scientific study and commercial gain but was unwilling to guarantee the benefits from future treatments.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more negotiations to secure a agreement suitable to both sides so the country's vital HIV treatment initiative can be sustained.
Broader Context
This development comes after a similar case in neighbouring Kenya, where a high court blocked a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
Since returning to the presidency recently, US President Donald Trump has slashed overseas assistance and closed the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen nations in Africa have so far agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
This assistance for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership might have yielded significant advantages for the people of Zimbabwe, especially the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Our nation was requested to surrender its biological resources and data indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," Mangwana explained.
"In essence, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our people should a future disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the US's withdrawal from the global health body and its pursuit of bilateral deals were upending systems previously set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing framework designed to deal with potential pandemics.
"This system is designed to ensure that when a country provides its data, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections over the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to ongoing discussions with our US partners on how subsequent collaboration might be arranged in a manner that respects the independence and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that negotiations must proceed since much of the nation's Aids initiatives relied on external financing.
"In cases where specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group commented.
The halted deal highlights the complex debate between receiving vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.